Further Information
E3 ubiquitin-protein ligase Midline-1, 632-, Midin, Putative transcription factor XPRF, RING finger protein 59, RING finger protein Midline-1, Tripartite motif-containing protein 18, MID1, FXY, RNF59, TRIM18, XPRF
For WB starting dilution is: 1:1000
The protein encoded by this gene is a member of the
tripartite motif (TRIM) family, also known as the 'RING-B
box-coiled coil' (RBCC) subgroup of RING finger proteins. The TRIM
motif includes three zinc-binding domains, a RING, a B-box type 1
and a B-box type 2, and a coiled-coil region. This protein forms
homodimers which associate with microtubules in the cytoplasm. The
protein is likely involved in the formation of multiprotein
structures acting as anchor points to microtubules. Mutations in
this gene have been associated with the X-linked form of Opitz
syndrome, which is characterized by midline abnormalities such as
cleft lip, laryngeal cleft, heart defects, hypospadias, and
agenesis of the corpus callosum. This gene was also the first
example of a gene subject to X inactivation in human while escaping
it in mouse. Multiple different transcript variants are generated
by alternate splicing; however, the full-length nature of some of
the variants has not been determined.
- Need, A.C., et al. Hum. Mol. Genet. 18(23):4650-4661(2009)
- Treutlein, J., et al. Arch. Gen. Psychiatry 66(7):773-784(2009)
- Styrkarsdottir, U., et al. Nat. Genet. 41(1):15-17(2009)
- Scapoli, L., et al. Eur. J. Oral Sci. 116(6):507-511(2008)
Supplied in PBS with 0.09% (W/V) sodium azide.
batch dependent
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
This MID1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 575-603 amino acids from the C-terminal region of human MID1.
4281
E3 ubiquitin-protein ligase Midline-1
MID1
Homo sapiens
Liquid
PREDICTED MOLECULAR WEIGHT:
75 kDa
O15344
This antibody is purified through a protein A column, followed by peptide affinity purification.
Cell Cycle
O15344
Optimal dilutions for each application to be determined by the researcher.